Dr. Nancy Bass, MD
NPI: 1821019555
Total Payments
$69,175
2024 Payments
$986.34
Companies
9
Transactions
102
Payment Breakdown by Category
Other$42,752 (61.8%)
Consulting$16,960 (24.5%)
Travel$5,814 (8.4%)
Food & Beverage$2,115 (3.1%)
Research$1,267 (1.8%)
Education$267.59 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,752 | 19 | 61.8% |
| Consulting Fee | $16,960 | 4 | 24.5% |
| Travel and Lodging | $5,814 | 23 | 8.4% |
| Food and Beverage | $2,115 | 47 | 3.1% |
| Unspecified | $1,267 | 3 | 1.8% |
| Education | $267.59 | 6 | 0.4% |
Payments by Type
General
$67,908
99 transactions
Research
$1,267
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $67,174 | 71 | $0 (2019) |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $1,160 | 3 | $0 (2024) |
| Eli Lilly and Company | $348.06 | 2 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $235.41 | 18 | $0 (2020) |
| AveXis | $130.50 | 2 | $0 (2019) |
| CATALYST PHARMACEUTICALS, INC. | $44.59 | 2 | $0 (2024) |
| UCB, Inc. | $40.98 | 2 | $0 (2022) |
| Astellas Pharma US Inc | $23.00 | 1 | $0 (2024) |
| Horizon Therapeutics plc | $18.16 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $986.34 | 4 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) ($918.75) |
| 2023 | $166.67 | 1 | Novartis Gene Therapies, Inc. (fka AveXis, Inc.) ($166.67) |
| 2022 | $208.14 | 4 | Eli Lilly and Company ($149.00) |
| 2021 | $274.06 | 2 | Eli Lilly and Company ($199.06) |
| 2020 | $26.63 | 2 | Sunovion Pharmaceuticals Inc. ($26.63) |
| 2019 | $11,921 | 21 | Biogen, Inc. ($11,710) |
| 2018 | $46,494 | 54 | Biogen, Inc. ($46,442) |
| 2017 | $9,098 | 14 | Biogen, Inc. ($9,021) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Education | Cash or cash equivalent | $31.10 | General |
| Category: NEUROLOGY | ||||||
| 11/13/2024 | CATALYST PHARMACEUTICALS, INC. | AGAMREE (Drug) | Education | Cash or cash equivalent | $13.49 | General |
| Category: NEUROLOGY | ||||||
| 05/29/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Biological | ||||||
| 02/09/2024 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | ZOLGENSMA (Drug) | — | Cash or cash equivalent | $918.75 | Research |
| Study: Research Medical Writing and Publication Support • Category: Neurology | ||||||
| 12/11/2023 | Novartis Gene Therapies, Inc. (fka AveXis, Inc.) | ZOLGENSMA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $166.67 | General |
| Category: GENE THERAPY | ||||||
| 08/04/2022 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: Neurology | ||||||
| 08/03/2022 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Neurology | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $149.00 | Research |
| Study: PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | ||||||
| 02/02/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: UPLIZNA | ||||||
| 12/16/2021 | Novartis Gene Therapies, Inc. (fka AveXis, Inc.) | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $75.00 | General |
| 02/18/2021 | Eli Lilly and Company | — | — | In-kind items and services | $199.06 | Research |
| Study: PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | ||||||
| 08/28/2020 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: CNS | ||||||
| 02/13/2020 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $11.29 | General |
| Category: CNS | ||||||
| 12/13/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $9.14 | General |
| Category: CNS | ||||||
| 11/11/2019 | AveXis | ZOLGENSMA (Biological) | Food and Beverage | In-kind items and services | $62.00 | General |
| Category: GENE THERAPY | ||||||
| 11/06/2019 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | Cash or cash equivalent | $115.68 | General |
| Category: NEUROLOGY | ||||||
| 10/23/2019 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,360.00 | General |
| Category: NEUROLOGY | ||||||
| 07/11/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: CNS | ||||||
| 06/07/2019 | AveXis | ZOLGENSMA (Biological) | Education | In-kind items and services | $68.50 | General |
| Category: GENE THERAPY | ||||||
| 06/05/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: CNS | ||||||
| 04/18/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: CNS | ||||||
| 03/08/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $9.41 | General |
| Category: CNS | ||||||
| 03/08/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $5.83 | General |
| Category: CNS | ||||||
| 02/28/2019 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,360.00 | General |
| Category: NEUROLOGY | ||||||
| 02/28/2019 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | Cash or cash equivalent | $112.58 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Research Medical Writing and Publication Support | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $918.75 | 1 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $348.06 | 2 |
About Dr. Nancy Bass, MD
Dr. Nancy Bass, MD is a Neurology with Special Qualifications in Child Neurology healthcare provider based in Milwaukee, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821019555.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nancy Bass, MD has received a total of $69,175 in payments from pharmaceutical and medical device companies, with $986.34 received in 2024. These payments were reported across 102 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($42,752).
Ad
Practice Information
- Specialty Neurology with Special Qualifications in Child Neurology
- Location Milwaukee, WI
- Active Since 07/21/2006
- Last Updated 09/12/2022
- Taxonomy Code 2084N0402X
- Entity Type Individual
- NPI Number 1821019555
Products in Payments
- SPINRAZA (Biological) $62,412
- ZOLGENSMA (Drug) $918.75
- ZOLGENSMA (Biological) $297.17
- APTIOM (Drug) $235.41
- AGAMREE (Drug) $44.59
- Nayzilam (Drug) $40.98
- Veozah (Drug) $23.00
- UPLIZNA (Drug) $18.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology with Special Qualifications in Child Neurology Doctors in Milwaukee
Dr. Ahmed Obeidat, M.d., P.h.d, M.D., P.H.D
Neurology with Special Qualifications in Child Neurology — Payments: $1.6M
Neurology with Special Qualifications in Child Neurology $1.6M
Dr. Avantika Singh
Neurology with Special Qualifications in Child Neurology — Payments: $634.74
Neurology with Special Qualifications in Child Neurology $634.74
Dr. Niyati Mehta, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $629.28
Neurology with Special Qualifications in Child Neurology $629.28
Dr. Lileth Joy Mondok, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $216.58
Neurology with Special Qualifications in Child Neurology $216.58
Pradeep Javarayee, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $139.25
Neurology with Special Qualifications in Child Neurology $139.25
Samuel Adams, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $122.17
Neurology with Special Qualifications in Child Neurology $122.17